Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 18, 2003, Pages 3079-3082

  Sayle, Kerry L ^a   Bentley, Johanne ^b   Boyle, F Thomas ^c   Calvert, A Hilary ^b   Cheng, Yuzhu ^b   Curtin, Nicola J ^b   Endicott, Jane A ^d   Golding, Bernard T ^a   Hardcastle, Ian R ^a   Jewsbury, Philip ^c   Mesguiche, Veronique ^a   Newell, David R ^b   Noble, Martin E M ^d   Parsons, Rachel J ^a   Pratt, David J ^d   Wang, Lan Z ^b   Griffin, Roger J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IC 50; STRUCTURE ACTIVITY RELATION;

EID: 12444339387     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00651-6     Document Type: Article

References (16)

1. Sherr C.J. Science. 274:1996;1672.
2. Malumbres M., Barbacid M. Nat. Rev. Cancer. 1:2001;222.
3. Senderowicz A.M., Sausville E.A. J. Natl. Cancer Inst. 92:2000;376.
4. Meijer, L.; Raymond, E. Acc. Chem. Res. 2003, 36, 417.
5. Sausville E.A. Trends. Mol. Med. 8:2002;S32.
6. Knockaert M., Greengard P., Meijer L. Trends Pharm. Sci. 23:2002;417.
7. Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. J. Med. Chem. 43:2000;1.
8. Hardcastle I.R., Golding B.T., Griffin R.J. Annu. Rev. Pharmacol. Toxicol. 42:2002;325.
9. Arris C.E., Boyle F.T., Calvert A.H., Curtin N.J., Endicott J.A., Garman E.F., Gibson A.E., Golding B.T., Grant S., Griffin R.J., Jewsbury P., Johnson L.N., Lawrie A.M., Newell D.R., Noble M.E.M., Sausville E.A., Schultz R., Yu W. J. Med. Chem. 43:2000;2797.
10. Gibson A.E., Arris C.E., Bentley J., Boyle F.T., Curtin N.J., Davies T.G., Endicott J.A., Golding B.T., Grant S., Griffin R.J., Jewsbury P., Johnson L.N., Mesguiche V., Newell D.R., Noble M.E.M., Tucker J.A., Whitfield H.J. J. Med. Chem. 45:2002;3381.
11. Mesguiche V., Parsons R.J., Arris C.E., Bentley J., Boyle F.T., Calvert A.H., Curtin N.J., Davies T.G., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Jewsbury P., Johnson L.N., Newell D.R., Noble M.E.M., Wang L.Z., Hardcastle I.R. Bioorg. Med. Chem. Lett. 13:2003;217.
12. Davies T.G., Bentley J., Arris C.E., Boyle F.T., Curtin N.J., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Hardcastle I.R., Jewsbury P., Johnson L.N., Mesguiche V., Newell D.R., Noble M.E.M., Tucker J.A., Wang L., Whitfield H.J. Nat. Struct. Biol. 9:2002;745.
13. 1H NMR, IR, UV) and analytical (elemental analysis and/or LC-MS) data fully consistent with the assigned structures.
14. Hardcastle, I. R.; Arris, C. E.; Bentley, J.; Boyle, F. T,; Calvert, A. H.; Curtin, N. J.; Davies, T. G.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Menyerol, J.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Tucker, J. A.; Wang, L.; Whitfield, H. J.; Manuscript in preparation.
15. PDB code 10GU. Crystallographic R-factor=20%; free R-factor=26%.
16. Fletcher D.A., McMeeking R.F., Parkin D.J. Chem. Inf. Comput. Sci. 36:1996;746.